Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Labopin, Myriam  [Clear All Filters]
2022
Duque-Afonso J, Finke J, Labopin M, Craddock C, Protheroe R, Kottaridis P, Tholouli E, Byrne JL, Orchard K, Salmenniemi U, et al. Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2022.
Ruggeri A, Galimard J-E, Labopin M, Rafii H, Blaise D, Ciceri F, Diez-Martin J-L, Cornelissen J, Chevallier P, Sanchez-Guijo F, et al. Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myeloid leukemia, a study on behalf of Eurocord and ALWP-EBMT. Transplant Cell Ther. 2022.
Battipaglia G, Labopin M, Blaise D, Díez-Martín JLuis, Bazarbachi A, Vitek A, Chevallier P, Castagna L, Grillo G, Daguindau E, et al. Impact of the addition of antithymocyte globulin to post-transplant cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplant cyclophosphamide alone in acute myeloid leukemia: a retrospective study on behalf of t. Transplant Cell Ther. 2022.
Devillier R, Galimard J-E, Labopin M, Blaise D, Raiola AMaria, Pavlu J, Castagna L, Socié G, Chalandon Y, Martino M, et al. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transplant. 2022.
Swoboda R, Labopin M, Giebel S, Schroeder T, Kröger N, Arat M, Savani B, Spyridonidis A, Hamladji R-M, Potter V, et al. Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par. Bone Marrow Transplant. 2022.
2021
Shouval R, Fein JA, Labopin M, Cho C, Bazarbachi A, Baron F, Bug G, Ciceri F, Corbacioglu S, Galimard J-E, et al. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematol. 2021;8(3):e205-e215.
Nagler A, Labopin M, Dholaria B, Wu D, Choi G, Aljurf M, Ciceri F, Gedde-Dahl T, Meijer E, Niittyvuopio R, et al. Graft-Versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. Transplant Cell Ther. 2021.
Kharfan-Dabaja MA, Labopin M, Brissot E, Kröger N, Finke J, Ciceri F, Deconinck E, Blaise D, Chevallier P, Gramatzki M, et al. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. Br J Haematol. 2021.
2020
Maffini E, Labopin M, Blaise D, Ciceri F, Gulbas Z, Deconinck E, Leblond V, Chevallier P, Socié G, Araujo MColorado, et al. CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the European. Am J Hematol. 2020.
Paviglianiti A, Labopin M, Blaise D, Socié G, Bulabois CEric, Lioure B, Ceballos P, Blau IWolfgang, Guillerm G, Maertens J, et al. Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT. Bone Marrow Transplant. 2020.
Peric Z, Labopin M, Peczynski C, Polge E, Cornelissen J, Carpenter B, Potter M, Malladi R, Byrne J, Schouten H, et al. Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant. 2020.
Rodríguez-Arbolí E, Labopin M, Tischer J, Brecht A, Ganser A, Finke J, Blau IWolfgang, Kröger N, Kalhs P, Forcade E, et al. FLAMSA-based reduced intensity conditioning versus myeloablative conditioning in younger patients with relapsed/refractory acute myeloid leukemia with active disease at the time of allogeneic stem cell transplantation: an ALWP/EBMT analysis. Biol Blood Marrow Transplant. 2020.
Bazarbachi A, Labopin M, Angelucci E, Gulbas Z, Ozdoğu H, Arat M, de Rosa L, Pastano R, Pioltelli P, Montserrat R, et al. Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party. Biol Blood Marrow Transplant. 2020.
Willasch AManfred, Peters C, Sedlacek P, Dalle J-H, Kitra-Roussou V, Yeşilipek A, Wachowiak J, Lankester A, Prete A, Hamidieh AAli, et al. Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study. Bone Marrow Transplant. 2020.
Botti S, van der Werf S, Stringer J, Eeltink C, Murray J, Ciceri F, Babic A, Duarte RF, Labopin M, Peczynski C, et al. Nutritional support in stem cell transplantation programs: Results from a multicenter survey of nurses on behalf of the Nurses Group and Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation and the Gruppo Ita. Nutrition. 2020;79-80:110998.
Battipaglia G, Labopin M, Hamladji R-M, Blaise D, Chevallier P, Brissot E, Gerbitz A, Socié G, Afanasyev B, Ciceri F, et al. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party o. Cancer. 2020.
Shouval R, Labopin M, Bomze D, Baerlocher GM, Capria S, Blaise D, Hänel M, Forcade E, Huynh A, Saccardi R, et al. Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. Bone Marrow Transplant. 2020.
Le Bourgeois A, Labopin M, Marçais A, de Latour RPeffault, Blaise D, Chantepie S, N'Guyen S, Maillard N, Forcade E, Yakoub-Agha I, et al. Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC. Ann Hematol. 2020.
Ruggeri A, Labopin M, Battipaglia G, Chiusolo P, Tischer J, Diez-Martin JLuiz, Bruno B, Castagna L, Moiseev ISergeevich, Vitek A, et al. The timing of post-transplant cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the ALWP of the EBMT. Biol Blood Marrow Transplant. 2020.
2019
Bazarbachi AHamid, Hamed RAl, Labopin M, Afanasyev B, Hamladji R-M, Beelen D, Eder M, Scheid C, Wu D, Bunjes D, et al. Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2019.
Shimoni A, Labopin M, Savani B, Byrne M, Volin L, Finke J, Niederwieser D, Ehninger G, Blaise D, Beelen D, et al. Comparable Long-Term Outcome after Allogeneic Stem-Cell Transplantation from Sibling and Matched Unrelated Donors in AML Patients Older than 50 years. A Report on Behalf of the ALWP of EBMT. Biol Blood Marrow Transplant. 2019.
Santoro N, Labopin M, Ciceri F, van Lint MTeresa, Nasso D, Blaise D, Arcese W, Tischer J, Bruno B, Ehninger G, et al. Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia over 45 years of age. Cancer. 2019.
Shouval R, Labopin M, Gorin NC, Bomze D, Houhou M, Blaise D, Zuckerman T, Baerlocher GM, Capria S, Forcade E, et al. Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia. Cancer. 2019.
Ringdén O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, Niederwieser D, Finke J, Stelljes M, Gerbitz A, et al. OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OVER 69 YEARS OF AGE WITH ACUTE MYELOID LEUKEMIA: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT. Biol Blood Marrow Transplant. 2019.
Nagler A, Labopin M, Dholaria B, Finke J, Brecht A, Schanz U, Niittyvuopio R, Neubauer A, Bornhäuser M, Santarone S, et al. Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2019.

Pages